Close Menu

Aspergillus

NEW YORK (GenomeWeb) — Molecular testing methods such as nucleic acid sequence-based amplification (NASBA) and qPCR, administered either in combination or separately, are superior to routinely used ELISA-based assays for diagnosing invasive aspergillosis, according to a newly published retrospect

Irish clinical diagnostics company Trinity Biotech has acquired the blood bank screening and certain molecular assets of UK-based personalized medicine and clinical diagnostics firm Lab21, the companies said today.

BD Diagnostics, a segment of Becton Dickinson, and Lab 21 will develop the real-time PCR-based test as an in vitro diagnostic product.

Today's announcement is in line with BD's plans to bring new assays to the BD Max System in a "broad range" of diseases.

Gen-Probe's Prodesse ProAdeno+ assay; Myconostica's MycAssay Aspergillus test; Warnex launches Septin9 test in Canada.

Myconostica's MycAssay Aspergillus gets CE mark for serum.

The UK-based company also signed on Inverness Medical Canada to distribute its products in the country.

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.